Welcome to our dedicated page for NexGel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on NexGel stock.
NexGel, Inc (symbol: NXGL) specializes in the manufacture of advanced hydrogel solutions. The company's core business revolves around creating unique trans-dermal delivery systems initially developed and FDA-approved for the hospital wound care market. Today, NexGel has expanded its offerings to include consumer over-the-counter (OTC) products, prescription (Rx) applications, medical devices, and cosmetic products.
NexGel Inc is renowned for its high water content, electron beam cross-linked, aqueous polymer hydrogels. These gels are integral to various applications such as wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company's expertise lies in producing custom gels utilizing proprietary manufacturing technologies. The hydrogels and consumer products are created through a combination of proprietary and non-proprietary mixing, coating, and cross-linking technologies.
The company's recent achievements and current projects highlight its ongoing commitment to innovation and excellence in the hydrogel market. NexGel continually explores new partnerships and collaborations to enhance its product offerings and market reach.
For investors and stakeholders, it is important to note the company's strategic communications are managed by KCSA, with Valter Pinto serving as the Managing Director. NexGel’s financial condition and market performance are presented through regular updates, ensuring transparency and keeping investors well-informed.
For the latest developments, financial updates, and detailed information about NexGel, Inc, please refer to the following contact details:
Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications
Phone: 212.896.1254
Email: valter@kcsa.com
NEXGEL, Inc. (NASDAQ: NXGL) reported a 48% year-over-year revenue increase to $396 thousand for Q1 2022, driven by new product launches in its consumer segment. The company introduced two new OTC products: the MEDAGEL ClearComfort Hydrogel Patch and the MEDAGEL Bug Bite Relief Patch. Gross loss improved to $22 thousand from $42 thousand last year, although operating expenses rose to $790 thousand. Cash reserves decreased to $10.5 million due to principal payments on notes payable. The company forecasts continued revenue growth.
NEXGEL, a provider of high-water-content hydrogel products, will announce its first quarter 2022 financial and operating results on May 12, 2022, after market closure. A conference call is scheduled for 4:30 PM/ET on the same day to discuss these results. The call can be accessed via toll-free numbers and will be webcast live, with an archive available for 90 days. The company specializes in skin-friendly hydrogels, developing over 200 combinations using natural ingredients for long-term wear with minimal irritation.
NEXGEL, a provider of high-water-content hydrogel products, announces CEO Adam Levy's participation at the Planet MicroCap Showcase 2022 from May 3-5, 2022, in Las Vegas. Levy's presentation is scheduled for May 4, 2022, at 10:30 AM PT, with a webcast accessible for those unable to attend. Interested investors can book 1x1 meetings during the conference. NEXGEL specializes in gentle skin patches utilizing over 200 formulations and has been developing hydrogels for over 20 years.
NexGel, Inc. (NASDAQ: NXGL), a leader in ultra-gentle hydrogel products, will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. CEO Adam Levy's presentation will be available on-demand at the conference's start. Attendees can register to join here. With over two decades of experience, NexGel specializes in high-water-content hydrogels for healthcare and consumer use.
NEXGEL, a provider of hydrogel products, reported a significant 130% year-over-year revenue growth for 2021, totaling $1.55 million. The fourth quarter saw a revenue increase of 428%, amounting to $533 thousand.
The company completed a $14.2 million IPO and has a cash reserve of $13.35 million as of December 31, 2021, supporting future growth initiatives. Operating expenses rose to $2.58 million, primarily due to one-time costs from the IPO. Despite growth, NEXGEL reported an EBITDA loss of $2.27 million for the year.
NEXGEL, a provider of high-water-content hydrogel products, will report its fourth quarter and full year 2021 financial results on March 21, 2022, after market closure. The company will host a conference call at 4:30 p.m. ET the same day to discuss these results, which will be available for streaming via its Investor Relations website. NEXGEL is known for formulating gentle skin patches utilizing natural ingredients, with over 200 combinations developed over two decades.
NEXGEL, Inc. (NASDAQ: NXGL) launched its new MEDAGEL Bug Bite Relief Patch on February 15, 2022. These patches are designed to provide instant relief for insect bites, using NEXGEL's high-water-content hydrogel technology. Infused with Arnica flower and Lidocaine, the patches are skin-friendly, chemical-free, and latex-free. They stay securely in place without irritation upon removal. The product is now available for purchase on Amazon.com.
NEXGEL, a leader in high-water-content hydrogel products, announced the launch of its new MEDAGEL ClearComfort Hydrogel Patch on January 12, 2022. Designed to prevent and treat foot blisters, these patches utilize advanced hydrogel technology to provide cushioning and protection against friction without leaving sticky residues. Available in customizable shapes, they cater to various footwear needs. CEO Adam Levy emphasized the product's ability to enhance comfort while addressing a common issue faced by consumers globally. The patches can be purchased on Amazon.com.
NEXGEL, a manufacturer of high-water-content hydrogels, provided a year-in-review for 2021, highlighting significant investments in its cGMP facility and the establishment of a robust executive and marketing team. NEXGEL focuses on three business segments: Consumer products like MedaGel and LumaGel, a Custom and White Label strategy for OTC brands, and Medical Devices like the NEXDrape. As of December 31, 2021, the company had 5.6 million shares outstanding and $13.3 million in cash, following a successful IPO that raised $14.2 million.
NexGel, Inc. (NASDAQ: NXGL, NXGLW), based in Langhorne, Pa., specializes in high water-content hydrogels for healthcare and cosmetics. On January 4, 2022, it announced that CEO Adam Levy will present at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. Levy's presentation will be available on-demand starting January 10th at 7:00 a.m. ET. For details, attendees can register here. NexGel has developed over 200 hydrogel combinations for gentle skin applications.
FAQ
What is the current stock price of NexGel (NXGL)?
What is the market cap of NexGel (NXGL)?
What does NexGel, Inc specialize in?
What are the primary applications of NexGel's products?
What is unique about NexGel's manufacturing technology?
Who handles investor relations for NexGel?
How did NexGel begin its journey in the hydrogel market?
What is the significance of NexGel’s hydrogels in consumer products?
How can one stay updated with NexGel's latest news and developments?
What financial information is available for NexGel investors?
Where can I find more detailed information about NexGel, Inc?
